Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody

Recent reports have shown limited anticancer therapeutic efficacy of insulin-like growth factor receptor (IGF-1R)-targeted monoclonal antibodies (mAbs), but the resistance mechanisms have not been completely identified. Because cooperation between epidermal growth factor receptor (EGFR) and IGF-IR c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shin, Dong Hoon, Min, Hye-Young, El-Naggar, Adel K., Lippman, Scott M., Glisson, Bonnie, Lee, Ho-Young
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3237768/
https://ncbi.nlm.nih.gov/pubmed/21980128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-11-0235
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares